Coenzyme Q and protein/lipid oxidation in a BSE-infected transgenic mouse model

Free Radical Biology and Medicine

Volumn 42, Issue 11, 2007, Pages 1723-1729

  Martin, Sergio F ^a   Burón, Isabel ^b   Espinosa, Juan C ^a   Castilla, Joaquín ^a   Villalba, José M ^b   Torres, Juan M ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Antioxidant; BSE; CoQ; Free radicals; Oxidative stress; Prion disease; PrP

Indexed keywords

PRION PROTEIN; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN TISSUE; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; INOCULATION; LIPID OXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; TRANSGENIC MOUSE;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; BRAIN; CATTLE; COENZYMES; DISEASE MODELS, ANIMAL; ENCEPHALOPATHY, BOVINE SPONGIFORM; LIPID METABOLISM; MICE; MICE, TRANSGENIC; OXIDATION-REDUCTION; OXIDATIVE STRESS; PRIONS; PRPSC PROTEINS; UBIQUINONE; UP-REGULATION;

BOVINAE; MUS; MUS MUSCULUS;

EID: 34247228759     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.03.005     Document Type: Article

References (65)

1. Pappolla M.A., Chyan Y.J., Omar R.A., Hsiao K., Perry G., Smith M.A., and Bozner P. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152 (1998) 871-877
2. Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., and Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70 (1998) 2212-2215
3. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17 (1997) 2653-2657
4. Beal M.F., Ferrante R.J., Browne S.E., Matthews R.T., Kowall N.W., and Brown Jr. R.H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42 (1997) 644-654
5. Browne S.E., Ferrante R.J., and Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 9 (1999) 147-163
6. Cookson M.R., and Shaw P.J. Oxidative stress and motor neurone disease. Brain Pathol. 9 (1999) 165-186
7. Carri M.T., Ferri A., Cozzolino M., Calabrese L., and Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res. Bull. 61 (2003) 365-374
8. Perry G., Nunomura A., Hirai K., Zhu X., Perez M., Avila J., Castellani R.J., Atwood C.S., Aliev G., Sayre L.M., Takeda A., and Smith M.A. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic. Biol. Med. 33 (2002) 1475-1479
9. Lopez M.F., and Melov S. Applied proteomics: mitochondrial proteins and effect on function. Circ. Res. 90 (2002) 380-389
10. Choi S.I., Ju W.K., Choi E.K., Kim J., Lea H.Z., Carp R.I., Wisniewski H.M., and Kim Y.S. Mitochondrial dysfunction induced by oxidative stress in the brains of hamsters infected with the 263 K scrapie agent. Acta Neuropathol. (Berl.) 96 (1998) 279-286
11. Kim B.H., Lee H.G., Choi J.K., Kim J.I., Choi E.K., Carp R.I., and Kim Y.S. The cellular prion protein (PrPC) prevents apoptotic neuronal cell death and mitochondrial dysfunction induced by serum deprivation. Brain Res. Mol. Brain Res. 124 (2004) 40-50
12. Requena J.R., Groth D., Legname G., Stadtman E.R., Prusiner S.B., and Levine R.L. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proc. Natl. Acad. Sci. USA 98 (2001) 7170-7175
13. Guentchev M., Voigtlander T., Haberler C., Groschup M.H., and Budka H. Evidence for oxidative stress in experimental prion disease. Neurobiol. Dis. 7 (2000) 270-273
14. Wong B.S., Brown D.R., Pan T., Whiteman M., Liu T., Bu X., Li R., Gambetti P., Olesik J., Rubenstein R., and Sy M.S. Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. J. Neurochem. 79 (2001) 689-698
15. Guan Z., Soderberg M., Sindelar P., Prusiner S.B., Kristensson K., and Dallner G. Lipid composition in scrapie-infected mouse brain: prion infection increases the levels of dolichyl phosphate and ubiquinone. J. Neurochem. 66 (1996) 277-285
16. Choi S.I., Ju W.K., Choi E.K., Kim J., Lea H.Z., Carp R.I., Wisniewski H.M., and Kim Y.S. Mitochondrial dysfunction induced by oxidative stress in the brains of hamsters infected with the 263 K scrapie agent. Acta Neuropathol. 96 (1998) 279-286
17. Kim N.H., Park S.J., Jin J.K., Kwon M.S., Choi E.K., Carp R.I., and Kim Y.S. Increased ferric iron content and iron-induced oxidative stress in the brains of scrapie-infected mice. Brain Res. 884 (2000) 98-103
18. Andreoletti O., Levavasseur E., Uro-Coste E., Tabouret G., Sarradin P., Delisle M.B., Berthon P., Salvayre R., Schelcher F., and Negre-Salvayre A. Astrocytes accumulate 4HNE adducts in murine scrapie and human Creutzfeldt-Jakob disease. Neurobiol. Dis. 11 (2002) 386-393
19. Brazier M.W., Lewis V., Ciccotosto G.D., Klug G.M., Lawson V.A., Cappai R., Ironside J.W., Masters C.L., Hill A.F., White A.R., and Collins S. Correlative studies support lipid peroxidation is linked to PrP(res) propagation as an early primary pathogenic event in prion disease. Brain Res. Bull. 68 (2006) 346-354
20. Wong B.S., Chen S.G., Colucci M., Xie Z., Pan T., Liu T., Li R., Gambetti P., Sy M.S., and Brown D.R. Aberrant metal binding by prion protein in human prion disease. J. Neurochem. 78 (2001) 1400-1408
21. Guentchev M., Siedlak S.L., Jarius C., Tagliavini F., Castellani R.J., Perry G., Smith M.A., and Budka H. Oxidative damage to nucleic acids in human prion disease. Neurobiol. Dis. 9 (2002) 275-281
22. 10 inhibits Bax-induced destabilization of mitochondria in mammalian cells. Apoptosis 11 (2006) 1359-1369
23. 10: an update. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 641-646
24. 2+-dependent sphingomyelinase by ubiquinol-mediated plasma membrane electron transport. Protoplasma 221 (2003) 109-116
25. Martin S.F., Gomez-Diaz C., Navas P., and Villalba J.M. Ubiquinol inhibition of neutral sphingomyelinase in liver plasma membrane: specific inhibition of the Mg(2+)-dependent enzyme and role of isoprenoid chain. Biochem. Biophys. Res. Commun. 297 (2002) 581-586
26. Fernandez-Ayala D.J., Martin S.F., Barroso M.P., Gomez-Diaz C., Villalba J.M., Rodriguez-Aguilera J.C., Lopez-Lluch G., and Navas P. Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid. Redox Signaling 2 (2000) 263-275
27. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA 95 (1998) 8892-8897
28. 10. Ann. Neurol. 41 (1997) 160-165
29. 10 tolerability in Huntington's disease. Mov. Disord. 11 (1996) 321-323
30. 10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22 (2002) 1592-1599
31. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59 (2002) 1541-1550
32. Castilla J., Gutierrez Adan A., Brun A., Pintado B., Ramirez M.A., Parra B., Doyle D., Rogers M., Salguero F.J., Sanchez C., Sanchez-Vizcaino J.M., and Torres J.M. Early detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch. Virol. 148 (2003) 677-691
33. Castilla J., Gutierrez-Adan A., Brun A., Pintado B., Parra B., Ramirez M.A., Salguero F.J., Diaz San Segundo F., Rabano A., Cano M.J., and Torres J.M. Different behavior toward bovine spongiform encephalopathy infection of bovine prion protein transgenic mice with one extra repeat octapeptide insert mutation. J. Neurosci. 24 (2004) 2156-2164
34. Castilla J., Brun A., San Segundo F., Salguero F.J., Gutiérrez-Adán A., Pintado B., Ramírez M.A., del Riego L., and Torres J.M. Vertical transmission of BSE prions evaluated in transgenic mouse model. J. Virol. 79 (2005) 8665-8668
35. Scott M., Foster D., Mirenda C., Serban D., Coufal F., Walchli M., Torchia M., Groth D., Carlson G., DeArmond S.J., et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59 (1989) 847-857
36. Scott M., Groth D., Foster D., Torchia M., Yang S.L., DeArmond S.J., and Prusiner S.B. Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 73 (1993) 979-988
37. Brun A., Castilla J., Ramirez M.A., Prager K., Parra B., Salguero F.J., Shiveral D., Sanchez C., Sanchez-Vizcaino J.M., Douglas A., and Torres J.M. Proteinase K enhanced immunoreactivity of the prion protein-specific monoclonal antibody 2A11. Neurosci. Res. 48 (2004) 75-83
38. Salguero F.J., Diaz-San S.F., Brun A., Cano M.J., and Torres J.M. Comparison of three monoclonal antibodies for use in immunohistochemical detection of bovine spongiform encephalopathy protease-resistant prion protein. J. Vet. Diagn. Invest. 18 (2006) 106-109
39. Navarro F., Arroyo A., Martin S.F., Bello R.I., de Cabo R., Burgess J.R., Navas P., and Villalba J.M. Protective role of ubiquinone in vitamin E and selenium-deficient plasma membranes. Biofactors 9 (1999) 163-170
40. 2+-dependent sphingomyelinase by ubiquinol-mediated plasma membrane electron transport. Protoplasma 221 (2003) 109-116
41. Levine R.L., Williams J.A., Stadtman E.R., and Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 233 (1994) 346-357
42. Oliver C.N. Measurement of oxidized proteins in systems involving activated neutrophils or HL-60 cells. Methods Enzymol. 186 (1990) 575-579
43. Carney J.M., Starke-Reed P.E., Oliver C.N., Landum R.W., Cheng M.S., Wu J.F., and Floyd R.A. Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc. Natl. Acad. Sci. USA 88 (1991) 3633-3636
44. 2+ in the presence of xylenol orange. Free Radic. Res. 31 (1999) 237-244
45. Migliorea L., Fontanaa I., Colognatoa R., Coppedea F., Sicilianob G., and Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol. Aging 26 (2005) 587-595
46. Serra J.A., Dominguez R.O., de Lustig E.S., Guareschi E.M., Famulari A.L., Bartolome E.L., and Marschoff E.R. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J. Neural Transm. 108 (2001) 1135-1148
47. Mecocci P., Polidori C., Cherubini A., Chionne F., Cecchetti R., and Senin U. Oxidative damage to DNA lymphocytes from AD patients. Neurology 51 (1998) 1014-1017
48. Mecocci P., Polidori M.C., Cherubini A., Ingegni T., Mattioli P., Catani M., Rinaldi P., Cecchetti R., Stahl W., Senin U., and Beal M.F. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch. Neurol. 59 (2002) 794-798
49. Choi J., Malakowsky C.A., Talent J.M., Conrad C.C., and Gracy R.W. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293 (2002) 1566-1570
50. Conrad C.C., Marshall P.L., Talent J.M., Malakowsky C.A., Choi J., and Gracy R.W. Oxidized proteins in Alzheimer's plasma. Biochem. Biophys. Res. Commun. 275 (2000) 678-681
51. Cecchi C., Fiorillo C., Sorbi S., Latorraca S., Nacmias B., Bagnoli S., Nassi P., and Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic. Biol. Med. 33 (2002) 1372-1379
52. Bogdanov M., Brown R.H., Matson W., Smart R., Hayden D., O'Donnell H., Flint Beal M., and Cudkowicz. Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 29 (2000) 652-658
53. Bonnefont-Rousselot D., Lacomblez L., Jaudon M., Lepage S., Salachas F., Bensimon G., Bizard C., Doppler V., Delattre J., and Meininger V. Blood oxidative stress in amyotrophic lateral sclerosis. J. Neurol. Sci. 178 (2000) 57-62
54. Simpson E.P., Henry Y.K., Henkel J.S., Smith R.G., and Appel S.H. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62 (2004) 1758-1765
55. Sayre L.M., Smith M.A., and Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8 (2001) 721-738
56. Zarkovic K. 4-Hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med. 24 (2003) 293-303
57. Good P.F., Hsu A., Werner P., Perl D.P., and Olanow C.W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57 (1998) 338-342
58. 10 as a potential treatment. J. Bioenerg. Biomembr. 36 (2004) 381-386
59. 10 in neurodegenerative diseases. Methods Enzymol. 382 (2004) 473-487
60. 10 and idebenone. J. Neurol. Sci. 90 (1989) 263-271
61. 10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 9 (1999) 261-266
62. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5 (2004) 373-384
63. Zhang Y., Aberg F., Appelkvist E.L., Dallner G., and Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. 125 (1995) 446-453
64. Zhang H.Y. Same causes, same cures. Biochem. Biophys. Res. Commun. 351 (2006) 578-581
65. 10 in rat. Free Radic. Biol. Med. 34 (2003) 563-575